Journey Medical (DERM) Up as FDA Accepts Skin Disease Drug NDA
Journey Medical (DERM) Zacks Investment Research·2024-03-19 21:51新药申请 - Journey Medical Corporation宣布其关键候选药物DFD-29胶囊（40mg）的新药申请（NDA）已被FDA接受审查[1] 临床试验结果 - DFD-29在两项III期研究（MVOR-1和MVOR-2）中表现出对治疗酒渣鼻的显著疗效，超过了标准治疗Oracea和安慰剂[2] - DFD-29对酒渣鼻的红斑评估也表现出积极效果，可能改变酒渣鼻的治疗范式[3]